

**In collaboration with NATA:  
We want it quick and we want it now!**


# **Bloody perioperative case scenarios: Vote for personalized care**

Sibylle A. Kozek-Langenecker MD Prof. MBA  
Chairperson, Department of Anaesthesia & Intensive Care  
Evangelical Hospital Vienna

[www.perioperativebleeding.org](http://www.perioperativebleeding.org)  
[sibylle.kozek@aon.at](mailto:sibylle.kozek@aon.at)



## Which statement is correct?

- 15% 1. PBM = **P**eriooperative severe **B**leeding **M**anagement
- 2% 2. POB = **P**atient-**o**riented **B**estseller
- 84%  3. NATA = **N**etwork of **A**dvancement of **T**ransfusion **A**lternatives
- 0% 4. ESA = **E**uropean **S**ociety of **A**llergologists

# **Disclosure of potential conflicts of interest**

**honoraria for lectures & consulting,  
travel reimbursement:**

Baxter

B. Braun

Biotest

Boehringer Ingelheim

CSL Behring

Fresenius Kabi

Mitsubishi Pharma

Novo Nordisk

Octapharma

Pfizer

TEM International

Verum Diagnostics

# Definitions of PeriOperative Bleeding

- minimal

- severe

- > 20% blood volume

- life-, organ-threatening

- e.g. intraoperative

- massive

- blood loss in 24 h

- blood loss in 3 h

- 50 ml/min in 20 mins

- > 1.5 ml/kg/min in 20 mins

- > 6 U PRBC in 24 h

therapy is more than just a reflex of  
1:1 plus cryo



# Severe **POB**

emergency

risk factor for anaemia

risk factor for transfusion

risk factor morbidity/mortality

increases resource use & costs



# Reductions in POB

- ✓ increased patient safety
- ✓ reduced incidence of

anaemia

allogeneic blood transfusion

coagulopathy

tissue hypoperfusion

**predictors for survival**

- ✓ job satisfaction, stress tolerance

# Contents


- eye-on workshop
- case discussions & voting
- e-tools for daily clinical practice



**„Time is life!“**




# Conventional coagulation tests






# Viscoelastic POC tests



**ROTEM® TEM Innovations**




**TEG Analyzer®, Haemoscope**

# **Viscoelastic point-of-care tests**

## **ROTEM / TEG**

# www.perioperativebleeding.org





# Algorithm & triggers

We recommend the application of transfusion algorithms incorporating **predefined transfusion triggers** to guide haemostatic intervention during intraoperative bleeding

**1B**

We recommend the application of transfusion algorithms incorporating predefined transfusion triggers **based on POC coagulation monitoring assays** to guide haemostatic intervention during cardiovascular surgery

**1C**

**protocolized care**


**=**

**personalized care**


# Thromboelastometry ROTEM®

→ clotting time (CT)

→ clot formation time (CFT) [sec]



# Normal ROTEM traces



# What does this ROTEM trace shows us?



59%

1. Normal EXTEM

25%

2. Normal INTEM

5%

3. Normal FibTEM

4%

4. Deteriorated HEPTM

7%

5. APTM showing hyperfibrinolysis






# How would the ROTEM trace look like if the patient is on aspirin?






- |     |    |                              |
|-----|----|------------------------------|
| 29% | 1. | CT EXTEM prolonged           |
| 28% | 2. | CT INTEM prolonged           |
| 17% | 3. | CT INTEM and EXTEM prolonged |
| 23% | 4. | No changes of normal tracing |
| 4%  | 5. | CT FIBTEM shortened          |

# Case 1 - intraoperative data in vascular surgery



# What could be the underlying coagulopathy?



22% 1. Dilutional coagulopathy


15% 2. Low platelet count

10% 3. Coumarin therapy


10% 4. Hyperfibrinolysis

42% 5. Heparin effect


# Confirmatory HEPTeM Assay



## Case 2 - intraOP data in intracranial surgery



# Diffuse bleeding: What is your next step?



34% 1. Administration of TXA

17% 2. Transfusion of FFP


18% 3. Transfusion of cryo

13% 4. Administration of protamin


18% 5. Transfusion of platelets

# Confirmatory APTEM Assay


**EXTEM**



**APTEM**




# Case 3 – severe postoperative bleeding



after 10 min






after 20 min

# Diffuse bleeding: What is your next step?

0' 1



0' 3



11



1. Administration of TXA

26%

2. Transfusion of FFP

42%

3. Transfusion of cryo

4%


4. Administration of protamin

17%

5. Transfusion of platelets

# Case 4 – no heparin has been given


0' 1



INTEM

St. : 12h30  
Run : 47.1 '  
CT : 576s  
CFT : 199s  
MCF : 63mm  
alp : 60°


0' 2



EXTEM

St. : 12h30  
Run : 46.4 '  
CT : 34s  
CFT : 107s  
MCF : 53mm  
alp : 73°


0' 3



FIBTEM

St. : 12h35  
Run : 41.4 '  
CT : 32s  
CFT : 999s  
MCF : 22mm  
alp : 41°

4



# Diffuse bleeding: What is your next step?


11% 1. TXA

11% 2. Protamin



29% 3. PCC

37% 4. FVIII


12% 5. FXIII



# Confirmatory ROTEM-modified test



Hemophilia A (FVIII 3%)



# Case 5 – severe bleeding during scoliosis repair



## EXTEM

CT:	166s	CFT:	297s	$\alpha$ :	44°
A15:	33mm	MCF:	38mm	ML:	- %

## FIBTEM

CT:	776s	CFT:	- s	$\alpha$ :	- °
A15:	3mm	MCF:	3mm	ML:	- %

# Which intervention has been done?



0%

1. TXA

100%

2. Protamin

0%

3. PCC

0%


4. FVIII C

0%



5. FIC

## **According to the ESA guidelines on severe perioperative bleeding management fibrinogen concentrate should be considered ...**

- 63%  1. if fibrinogen concentration is < 1.5-2 g/L (GRADE 1C)
- 22% 2. if there are signs of hypofibrinolysis in ROTEM or TEG
- 5% 3. if high fibrinogen function is suspected or proven
- 10% 4. if platelet aggregation is decreased




**Which is the recommended haemoglobin target in active severe perioperative bleeding according to the ESA guidelines?**

18% 1. 10-12 g/dl

5% 2. >13 g/dl

2% 3. 5 g/dl

75% 4. 7-9 g/dl



# e-tools for daily clinical practice: „applications“ for smartphone

- TIC app
- P P H app
- Dabigatran app
- Hip fracture app
- ABC guideline app
- ESA guideline webapp
- RA & anticoagulants app



Store

Mac

iPod

iPhone

iPad

iTunes

Support



# iTunes Preview

[Overview](#)[Features](#)[iTunes Charts](#)

## TiCapp

By OEGARI

Open iTunes to buy and download apps.

[View More By This Developer](#)[View In iTunes](#)**Free**

Category: Medical

Released: Feb 17, 2014

Version: 1.0

Size: 2.6 MB

Languages: English, German

Seller: Oesterreichische

Gesellschaft für

Anaesthesiologie, Reanimation  
und Intensivmedizin

© OEGARI

Rated 4+

**Compatibility:** Requires iOS  
6.0 or later. Compatible with



### Description

TiCapp offers the following applications:

a) scroll down the algorithm of pathophysiology-oriented TIC management

[TiCapp Support](#)[...More](#)

### iPhone Screenshots



Overview Features

[View More by This Developer](#)

By Cranworth Medical Ltd

Open iTunes to buy and download apps.

[View In iTunes](#)

 This app is designed for both iPhone and iPad

Free

Category: **Medical**

Released: 17 November 2013

Version: 1.1

Size: 4.3 MB

Language: English

Developer: Cranworth Medical

Ltd

© Cranworth Medical Ltd

Rated 12+ for the following:

Infrequent/Mild Alcohol.

Tobacco, or Drug Use or

## References

### Description

## Summary of the 2013 European trauma guidelines: A quick reference tool for clinicians



This clinical practice guideline provides evidence-based recommendations that aim to support the acute

**ABC-Trauma Support ▶**

[...More](#)

## Screenshots

iPhone | iPad



Auswählen

Seite ▾ Sicherheit ▾ Extras ▾ ?



## iTunes Preview

Überblick Features

## PPH App

von OEGARI

Öffnen Sie iTunes, um Apps zu kaufen und zu laden.

[Mehr von diesem Entwickler](#)[In iTunes ansehen](#)

## Gratis

Kategorie: Medizin

Erschienen: 30.03.2014

Version: 1.0

Größe: 1.0 MB

Sprachen: Deutsch, Englisch

Entwickler: Oesterreichische  
Gesellschaft für  
Anaesthesiologie, Reanimation  
und Intensivmedizin  
© ÖGARI

Freigabe 12+ für Folgendes:

Selten/schwach ausgeprägt:  
Gebrauch von Alkohol, Tabak  
oder Drogen bzw. Verweise  
hierzu**Kompatibilität:** Erfordert iOS  
6.0 oder neuer. Kompatibel mit  
iPhone, iPad und iPod touch.  
Diese App ist für iPhone 5  
optimiert.

## Kundenbewertungen

We haven't yet received any reviews.

## Beschreibung


OEGARI APP:

Die PPH App ist ausschließlich für Gesundheitsdienstleister gemacht, die Gebärende betreuen.

Die PPH App soll den Usern im Sinne einer Crisis Checklist helfen eine peri-partale Blutung zu managen.

[PPH App Support](#)

## iPhone Screenshots





# iTunes Preview

Überblick Features

## Dabigatran

von OEGARI

Öffnen Sie iTunes, um Apps zu kaufen und zu laden.

[Mehr von diesem Entwickler](#)



[In iTunes ansehen](#)

**Gratis**

Kategorie: **Medizin**

Erschienen: 19.12.2013

Version: 1.0

Größe: 0.8 MB

Sprachen: Deutsch, Englisch

Entwickler: Oesterreichische

Gesellschaft für

Anaesthesiologie, Reanimation

und Intensivmedizin

© 2013 OEGARI

Kennzeichnung: 4+

**Kompatibilität:** Erfordert iOS

6.0 oder neuer. Kompatibel mit

iPhone, iPad und iPod touch.

Diese App ist für iPhone 5

optimiert.

### Kundenbewertungen

Wir haben noch nicht genügend Bewertungen erhalten, um einen Durchschnittswert für die aktuelle Version dieses Artikels berechnen zu können.


### Beschreibung

Die Dabigatran App ist ausschließlich für Ärztinnen und Ärzte gemacht, die Patientinnen und Patienten mit einer Gerinnungshemmung durch das Medikament Pradaxa (RM) vor, während und nach Operationen bzw. bei Blutungsnotfällen behandeln.

[Dabigatran Support](#)

[...Mehr](#)

### iPhone Screenshots



# Eur J Anaesthesiol 2013; 30: 270-382

## GUIDELINES

### Management of severe perioperative bleeding

#### *Guidelines from the European Society of Anaesthesiology*

Sibylle A. Kozek-Langenecker, Arash Afshari, Pierre Albaladejo, Cesar Aldecoa Alvarez Santullano, Edoardo De Robertis, Daniela C. Filipescu, Dietmar Fries, Klaus Görlinger, Thorsten Haas, Georgina Imberger, Matthias Jacob, Marcus Lancé, Juan Llau, Sue Mallett, Jens Meier, Niels Rahe-Meyer, Charles Marc Samama, Andrew Smith, Cristina Solomon, Philippe Van der Linden, Annþ Juul Wikkelsø, Patrick Wouters and Piet Wyffels

The aims of severe perioperative bleeding management are three-fold. First, preoperative identification by anamnesis and laboratory testing of those patients for whom the perioperative bleeding risk may be increased. Second, implementation of strategies for correcting preoperative anaemia and stabilisation of the macro- and microcirculation. Third, to optimise the patient's tolerance of bleeding. The purpose of this guideline is to summarise current knowledge and to transfer this knowledge into daily patient care wherever possible. The Guidelines Committee of the European Society of Anaesthesiology (ESA) formed a task force with members of scientific subcommittees and individual expert members of the ESA. Electronic databases were searched without language restrictions from the year 2000 until 2012. These searches produced 20 664 abstracts. Relevant

systematic reviews with meta-analysis, randomised controlled trials, cohort studies, case-control studies, cross-sectional studies and case reports were included. The suggestion of the task force was to use the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. This report includes general recommendations as well as specific recommendations in various fields of surgical interventions. The final draft guideline was posted on the ESA website for four weeks and the link was sent to all ESA members. Comments were collated and the guidelines amended as appropriate. When the final draft was complete, the Guidelines Committee and ESA Board ratified the guidelines.

<http://esa.perioperativebleeding.org>

http://esa.perioperativebleeding.org/html/cardio.html?zoom\_highlight=cardiovascular Cardiovascular surgery

Konvertieren Auswählen

Seite Sicherheit Extras

Content

### Cardiovascular surgery

Withdrawal of aspirin therapy increases the risk of thrombosis; continuation of aspirin therapy increases the risk of bleeding. **A**

Withdrawal of clopidogrel therapy increases the risk of thrombosis; continuation of clopidogrel therapy increases the risk of bleeding. **A**

We recommend that a prophylactic dose of low molecular weight heparin should be administered subcutaneously 8–12 h before elective CABG surgery. This intervention does not increase the risk of perioperative bleeding. **1B**

We recommend that tranexamic acid or EACA should be considered before CABG surgery. **1A**

We suggest considering prophylactic preoperative infusion of 2 g fibrinogen concentrate in patients with fibrinogen concentration  $< 3.8 \text{ g l}^{-1}$ , because it may reduce bleeding following elective CABG surgery. **2C**

Prothrombin complex concentrate is effective for rapid reversal of oral anticoagulation before cardiac surgery. **A**

We recommend that intraoperative tranexamic acid or EACA administration should be considered to reduce perioperative bleeding in high-, medium- and low-risk cardiovascular surgery. **1A**

We recommend that tranexamic acid should be applied topically to the chest cavity to reduce postoperative blood loss following CABG surgery. **1C**

We recommend that fibrinogen concentrate infusion guided by point-of-care viscoelastic coagulation monitoring should be used to reduce perioperative blood loss in complex cardiovascular surgery. **1B**

cardiovascular

18:15  
03.09.2014



## 6: Alternatives and adjuncts to blood transfusion

### Essentials

- Transfusion alternatives were mostly developed to reduce blood use in surgery but have much wider application.
- They are most effective when used in combination and as part of a comprehensive patient blood management programme.
- Predeposit autologous blood donation before surgery is of uncertain benefit and now has very restricted indications in the UK.
- Intraoperative cell salvage (ICS) is effective (and may be life-saving) in elective or emergency high blood loss surgery and management of major haemorrhage.
- Postoperative cell salvage (PCS) and reinfusion can reduce blood use in joint replacement and scoliosis surgery.
- ICS and PCS are usually acceptable to Jehovah's Witnesses.
- Tranexamic acid (antifibrinolytic) is inexpensive, safe and reduces mortality in traumatic haemorrhage. It reduces bleeding and transfusion in many surgical procedures and may be effective in obstetric and gastrointestinal haemorrhage.
- Off-label use of recombinant activated Factor VII (rFVIIa) for haemorrhage does not reduce mortality and can cause serious thromboembolic complications.
- Erythropoiesis stimulating agents (ESAs), such as erythropoietin, are standard therapy in renal anaemia and can support blood conservation in some cancer chemotherapy patients and autologous blood donation programmes. They may also be effective in selected patients with myelodysplasia.
- ESAs may cause hypertension and thromboembolic problems. Careful monitoring is required to keep the haematocrit below 35%.

# „Translate“ guidelines into your clinical reality

## Checklist for the emergency management of severe or massive intraoperative bleeding at the Evangelical Hospital Vienna, Austria

1. Avoid hypothermia  $< 34^{\circ}\text{C}$ , pH  $< 7.2$ , hypocalcemia  $< 1 \text{ mmol/L}$
2. Careful surgical technique, permissive hypotension, increase tolerance to anemia.
3. Risk for (local) hyperfibrinolysis (e.g., orthopedic surgery with tourniquet, severe trauma, shock): prophylaxis with tranexamic acid 10–20 mg/kg.
4. In case of overt severe bleeding ( $> 20\%$  blood volume):
  - a. If hyperfibrinolysis (according to ROTEM or reptilase time): tranexamic acid 15–20 mg/kg (before any procoagulant therapy).
  - b. If fibrin deficit (FIBTEM A10  $< 10 \text{ mm}$ , fibrinogen concentration  $< 1.5 \text{ g/L}$ ): fibrinogen concentrate (dose calculation: approximately A10 increment  $\times 0.55$  or fibrinogen level increment  $\times 4$ ) (alternative: FFP  $> 30 \text{ mL/kg}$ ).
  - c. If thrombin generation deficit ( $> 250\%$  blood volume loss; EXTEM CT  $> 80 \text{ s}$  or indicative routine coagulation tests): prothrombin complex concentrate 20 U/kg (alternative: FFP  $> 30 \text{ mL/kg}$ ).
  - d. If platelet deficit (according to ROTEM or platelet counts  $< 50 \text{ G/L}$ ): platelet concentrate.
5. Only as an ultimate measure after surgical and pharmacological interventions have failed and only after “preconditioning” with supplementation of substrates (fibrinogen, platelets) at pH  $> 7.2$ : recombinant factor VIIa (off-label use).
6. In case of overt severe bleeding in the presence of a normal ROTEM and/or history of antiplatelet drugs ( $\pm$  indicative platelet function tests): desmopressin 0.3  $\mu\text{g/kg}$ , if non-responsive to platelet concentrates.
7. In case of overt severe bleeding and history of vitamin K antagonists: reversal with prothrombin complex concentrate (dose calculation; 25–50 U/kg adjusted to actual INR).
8. In case of overt severe bleeding and history of direct oral antagonists: consider last intake, renal function, active charcoal, hemo(dia)filtration, reversal with prothrombin complex concentrate.
9. After heparin: consider reversal with protamine.
10. If factor XIII deficit (or indicative ROTEM): consider factor XIII concentrate.

# Conclusions



**severe POB > 20 % loss in blood volume**

**therapy is a concert of targeted actions**

... heparin effect, hyperfibrinolysis, factor VIII deficiency, fibrinogen deficiency ...

... pathophysiology-oriented, fast, cost-effective ...

**ESA guidelines exist** EJA 2013; 30: 270